Investigational drug · Phase 3
Zelpultide
Also called: AT-100, rhSP-D
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bronchopulmonary Dysplasia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Zelpultide"
First trial start
2025
Feb 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zelpultide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bronchopulmonary Dysplasia
Largest trials
Live from ClinicalTrials.gov: studies naming "Zelpultide" as an intervention, largest first.
- Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)Pivotal-lookingRecruiting
Airway Therapeutics, Inc.Industry
NCT06897839 · 366 participants (planned) · Start Feb 3, 2025 · Primary completion Mar 31, 2028
Drug: Zelpultide alfa · For: Bronchopulmonary Dysplasia
Sites: Buenos Aires, Argentina; Antwerp, Belgium; Brussels, Belgium · 56 sites in all
Airway Therapeutics, Inc.Industry
NCT04659122 · 5 participants · Start Aug 17, 2021 · Primary completion Feb 23, 2023
Drug: AT-100 · For: COVID-19; Undefined
Sites: Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- Covalency competition in Ni-O-Mo bridging sites with enhanced Lewis acidity for efficient alkaline hydrogen evolution.
Wang Y, Tian S, Zhang K, et al. · J Colloid Interface Sci 2027
- Chiral-induced spin polarization in amorphous cobalt Iron hydroxide: Synergistic density of states and d-band modulation for efficient bifunctional water electrolysis.
Pan H, Wang Y, Han J, et al. · J Colloid Interface Sci 2027
- Preclinical evidence and mechanisms of icariin on bone health in ovariectomized rodent models of osteoporosis: A systematic review and meta-analysis.
Wang X, Zhou L, Shi T, et al. · J Ethnopharmacol 2027
- Anti-inflammatory and early osteogenic potential of a 96% ethanol extract of Drynaria bonii.
Tai DC, Trinh PTN, Nhut KDM, et al. · J Ethnopharmacol 2027
- Methanolic extract of Lippia graveolens (Mexican oregano) protects against iron- and lead-induced genomic damage without evidence of toxicity in CD-1 mice.
Alarcón-Herrera N, Abrica-González P, Flores-Maya S, et al. · J Ethnopharmacol 2027
- Acute and subacute toxicological evaluation of the alkaloid-rich fraction from Smyrnium olusatrum L. seeds in mice.
Sekkout Z, Boudaia O, De Palma G, et al. · J Ethnopharmacol 2027
Also in development for Bronchopulmonary Dysplasia
- Human umbilical cord blood-derived mesenchymal stem cellsSMUP-IA-01, mid-dosePhase 22 trials
Medipost Co Ltd. · Knee Osteoarthritis, Bronchopulmonary Dysplasia, BPD
- OHB-607Mecasermin RinfabatePhase 21 trial
OHB Neonatology Ltd. · Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.